Clinical Trials Logo

Filter by:
NCT ID: NCT06368167 Not yet recruiting - Follicular Lymphoma Clinical Trials

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma

NCT ID: NCT06368141 Not yet recruiting - Colon Cancer Clinical Trials

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

NeoCHIC
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn the effect of neoadjuvant chemotherapy plus sequential immune checkpoint inhibitor (ICI) therapy in locally advanced colon cancer. The main questions it aims to answer are: - Does this neoadjuvant chemotherapy increase the pathologic complete response (pCR) of locally advanced colon cancer? - Does this neoadjuvant chemotherapy improve the long-term survival of locally advanced colon cancer? Participants will receive: - a pre-operative CAPEOX (capecitabine oral + oxaliplatin i.v.)regimen. - a sequential CAPEOX plus Serplulimab regimen. - a standard complete mesocolic excision (CME) operation.

NCT ID: NCT06368037 Not yet recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Start date: August 2024
Phase: N/A
Study type: Interventional

This study is a prospective, single-center, single-group design exploratory clinical research. No control group is set, and only subjects meeting the indications of the study device are treated. After patients sign informed consent, they are screened, and those meeting the inclusion criteria are enrolled. The treatment involves using myocardial radiofrequency ablation system and catheter-based myocardial radiofrequency ablation needle and its guidance system for treating obstructive hypertrophic cardiomyopathy. All subjects are followed up before discharge, and at 30 days, 3 months, 6 months, and 12 months postoperatively.

NCT ID: NCT06367114 Not yet recruiting - Clinical trials for Relapsed or Refractory Acute Lymphoblastic Leukemia

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Start date: April 2024
Phase: Phase 2
Study type: Interventional

This study is a Phase II, single-arm, open-label, non-randomized, dose-escalation clinical trial to evaluate the efficacy and safety of ssCART-19 Cell Injection in the treatment of patients with CD19 positive Relapsed or Refractory acute lymphoblastic leukemia, including central nervous system infiltration.

NCT ID: NCT06366685 Not yet recruiting - Esophageal Cancer Clinical Trials

Development and Initial Application of a Combined Exercise and Psychological Intervention Program for Patients After Esophagectomy

Recovery
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Esophageal cancer imposes a significant burden in China, accounting for over 60% of the global disease burden. While surgery remains a common and highly effective treatment for esophageal cancer, patients often experience multiple physical and psychological symptoms postoperatively, severely affecting their recovery outcomes and quality of life. Although existing exercise or psychological intervention programs have shown some effectiveness, issues such as relatively singular intervention content, imprecise intervention timing, and vague intervention details persist. This project, based on previous research foundations (including the development of symptom measurement tools and the identification of key recovery periods), is guided by symptom management theory and knowledge translation models. Taking a perspective of the synergistic impact of physical and psychological symptoms, the study focuses on patients undergoing esophageal cancer surgery. Initially, evidence-based literature review, focus group interviews, and expert consultations were conducted to develop a combined exercise and psychological intervention program, integrating subjective (CSCA_EC) and objective (6MWT) measurement indicators, named "Recovery For EC." Subsequently, the program was preliminarily applied in clinical settings using a mixed-methods approach, combining quantitative quasi-experimental design (108 cases) and qualitative interviews to assess its acceptability. The final clinical trial version of the Recovery For EC program was developed to provide patients with a tool for self-monitoring recovery outcomes and offer clinical healthcare professionals guidance for implementing precise and personalized rehabilitation management.

NCT ID: NCT06366659 Not yet recruiting - Clinical trials for Intrahepatic Cholestasis of Pregnancy

Unraveling the Pathogenesis of Pruritus in Intrahepatic Cholestasis of Pregnancy

Start date: April 20, 2024
Phase:
Study type: Observational

This study hopes identify the main pruritogens of ICP pruritus and provide new insights for the diagnosis, prediction, and treatment of ICP. Details are as follows: It is planned to include ICP confirmed pregnant women and healthy pregnant women who have given birth in the Peking University Third Hospital and Sichuan University West China Second University Hospital. Then progesterone sulfate levels in plasma samples will be quantified by High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) and itch intensity will be quantified by questionnaires. Main study endpoint: To reveal new indicators of ICP diagnosis with high accuracy: single, multiple or combined indicators of progesterone sulfates and other molecules like bile acids; Secondary study endpoint: To determine whether progesterone sulfates can be used as an early screening indicator for ICP for disease prediction, specifically whether elevated levels of progesterone sulfates predate pruritus in pregnant women with ICP.

NCT ID: NCT06366516 Not yet recruiting - Clinical trials for Precancerous Cervical Lesion

Role of Methylation Test Triage in HPV Positive Women

MTTRIHPW
Start date: April 2024
Phase: N/A
Study type: Interventional

The pathological results were used as the gold standard in this study and the investigators analyze the diagnostic value of six gene methylation status (ASTN1 DLX1, ITGA4, RXFP3, SOX17, ZNF671) in triaging high-risk human papillomavirus infection. The sensitivity and specificity of methylation test and cytology in the diagnosis of high-grade cervical lesions are compared in order to providing new methods and basis in improving the accuracy of cervical cancer screening.

NCT ID: NCT06365697 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis

Start date: May 2024
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate effectiveness and safety of the Ton-bridge carotid stent for the treatment of carotid artery stenosis.

NCT ID: NCT06364969 Not yet recruiting - Cholestasis Clinical Trials

Investigation of the Pruritogens of Liver-related Diseases

Start date: April 20, 2024
Phase:
Study type: Observational

This study hopes investigate the itch-inducing ability of different potential pruritogen candidates of cholestasis pruritus, especially the intrahepatic cholestasis of pregnancy (ICP). In this study, a combination of skin application and needle-free subcutaneous injection was used to investigate whether human endogenous molecules can cause itching. And a questionnaire is used to quantify the intensity of different candidates-induced itch.

NCT ID: NCT06364904 Not yet recruiting - Bladder Cancer Clinical Trials

An Phase III Study, Multicenter,Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Start date: April 15, 2024
Phase: Phase 3
Study type: Interventional

The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.